INT194591

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.07
First Reported 2006
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 0.33
Pain Relevance 1.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ACR) DNA binding (ACR) protein complex (ACR)
ACR (Homo sapiens)
Pain Link Frequency Relevance Heat
Adalimumab 44 96.88 Very High Very High Very High
abatacept 238 89.88 High High
Infliximab 23 77.76 Quite High
Etanercept 18 75.36 Quite High
rheumatoid arthritis 147 70.32 Quite High
anakinra 2 61.32 Quite High
methotrexate 66 60.80 Quite High
Inflammation 15 5.00 Very Low Very Low Very Low
Pain 10 5.00 Very Low Very Low Very Low
Arthritis 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 71 97.36 Very High Very High Very High
Rheumatoid Arthritis 151 70.32 Quite High
Infection 31 5.00 Very Low Very Low Very Low
INFLAMMATION 26 5.00 Very Low Very Low Very Low
Disease Progression 10 5.00 Very Low Very Low Very Low
Pain 10 5.00 Very Low Very Low Very Low
Lung Cancer 10 5.00 Very Low Very Low Very Low
Cancer 9 5.00 Very Low Very Low Very Low
Necrosis 7 5.00 Very Low Very Low Very Low
Arthritis 6 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
When we grouped the patients on the basis of their clinical response (ACR improvement criteria) to adalimumab, a significant decrease in RF serum titers was observed in those who were clinically improved according to ACR 20 and ACR 50 at weeks 24 and 48, whereas a decrease was also found for ACR 70 at week 48 (Table 3).
Negative_regulation (decrease) of Gene_expression (found) of ACR associated with adalimumab
1) Confidence 0.07 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526573 Disease Relevance 0.13 Pain Relevance 0.20
Secondary endpoints included percentage of patients achieving ACR50 and ACR70 responses, remission according to DAS-28 (?
Negative_regulation (remission) of Gene_expression (responses) of ACR50
2) Confidence 0.05 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.10 Pain Relevance 0.51
Secondary endpoints included percentage of patients achieving ACR50 and ACR70 responses, remission according to DAS-28 (?
Negative_regulation (remission) of Gene_expression (responses) of ACR70
3) Confidence 0.05 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.10 Pain Relevance 0.51

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox